Summary

This single-blind prospective randomized study was designed to assess the efficacy and
safety of the use of Surgicel® compared to the use of conventional surgical procedures
(ligatures and bipolar electrocautery alone) to achieve hemostasis in thyroid surgery

Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.

Primary Outcomes

Measure

The primary endpoint of the study was the postoperative volume of wound drainage

time frame:
1 WEEK

Secondary Outcomes

Measure

The secondary endpoints were events of bleeding requiring wound exploration under anesthesia

time frame:
48 HOURS

duration of drain use

time frame:
1 WEEK

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria:
- All patients who required a thyroidectomy
Exclusion Criteria:
- Unwilling or unable to consent
- Age < 18 years
- known allergy to oxidized cellulose
- Inability to discontinue use of anticoagulants 10 days before surgery
- Coagulopathy that could not be corrected